We conducted a retrospective study to compare outcome in Caucasians and non-Caucasians undergoing standard sibling allogeneic SCT. End points of the study were to compare graft-versus-host disease (GvHD) occurrence and transplant-related mortality (TRM). There were 251 patients, 43 non-Caucasian and 208 Caucasian. A higher proportion of non-Caucasian patients developed acute GvHD (aGvHD) grade 2 or greater as compared to the Caucasian group (48 vs 26%, respectively) P ¼ 0.02. With a median follow-up of 27 months, 26% (11/43) of nonCaucasians and 14% (29/208) of Caucasian patients had died from TRM, which accounted for 55% of all deaths in the non-Caucasian group compared to 33% in Caucasians, P ¼ 0.02. Overall survival 12 months post transplant was 64 vs 69% in the non-Caucasian and Caucasian groups, respectively (P ¼ 0.43). Although there were higher numbers of CMV-positive patients in the non-Caucasian group, there were no deaths from CMV reactivation in this subgroup. We conclude that there is increased TRM and aGvHD following standard sibling allograft in the non-Caucasian population and this could be due to either differences in tumour biology or extrinsic factors such as socio-economic factors, nutritional status, post transplant care or presenting with late stage disease.
Introduction
Inferior survival amongst non-Caucasians has been observed following renal transplantation. This has been attributed to various factors such as socio-economic status, availability and usage of medical care facilities, psychosocial, cultural and biological factors. Previously published studies from the United States have shown that black patients were less likely to undergo renal transplantation. 1 Racial difference in survival has also been noted in childhood B-acute lymphoblastic leukaemia 2,3 where African Americans (AA) and Spanish surname (SS) children had shorter survivals compared to white children.
2 AA and SS children were noted to have more adverse prognostic factors at presentation.
Inferior outcome in ethnic minorities has also been noted in various malignancies such as prostatic carcinoma 4, 5 and breast malignancy. [6] [7] [8] Poor outcome is thought to be related to lower socio-economic status (SES). 4, [6] [7] [8] Adults of lower socio-economic status also tend to present with advanced stage disease at diagnosis. 6 In a recent study by the Cancer and Leukaemia study group B (CALGB), AA males were shown to have significantly lower complete remission (CR) and significantly poorer overall survival (OS) and disease-free survival (DFS) rates when treated with similar induction chemotherapeutic regimens. 9 Racial differences in disease biology and genetic heterogeneity could be contributing to the poor outcome.
2 Racial difference in drug response or drug metabolism may be contributing factors for higher rates of relapse or treatment failure. 10 If differences in survival and response rate are proven to be due to genetic differences in drug metabolism, individualising treatment according to pharmacokinetic profiles may improve survival in these ethnic subgroups.
Allogeneic stem cell transplantation (allo-SCT) remains the only curative option for various malignant and nonmalignant haematological conditions. Transplant-related mortality (TRM) varies from 5-50% depending on factors such as disease, stage of disease, age of the patient, sex, degree of HLA disparity, time to transplantation and CMV status.
The aim of the study was to ascertain whether there was a significant difference in outcome in non-Caucasians undergoing allogeneic transplantation when adjusted for age, gender, transplant-related factors (sex mismatch, graft source, CMV status, graft-versus-host disease (GvHD) prophylaxis, conditioning regimen) and stage of disease. The primary end point of the study was to compare TRM and GvHD between the two groups.
Patients and methods
This was a retrospective analysis of adult and paediatric patients undergoing standard sibling allogenic transplantation in two centres between 1998 and 2002 for acute lymphoid leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), Aplastic anaemia (AA) and Fanconi's anaemia (FA). Patients receiving unrelated donor transplantation were excluded from this study, as there was no patients in the nonCaucasian group who received unrelated donor transplantation. Data were retrieved from the database and case notes. All patients were followed up in the two centers. There were 208 patients in the white (Caucasian) group and 43 in the ethnic (non-Caucasian) group. The non-Caucasian group comprised of 19 (44%) South Asians, 15 (35%) Oriental/East Asian and nine (21%) African black patients.
Adult patients were categorized as good risk if they were transplanted for CML in chronic phase, ALL and AML first CR, myeloma post first line of treatment in either CR or partial remission (PR) and NHL in first CR/PR. Paediatric patients were considered to be good risk if transplanted for ALL in CR1 or CR2, AML in CR1, nonsevere Aplastic anaemia. Patients transplanted for FA were considered to be poor risk.
The majority of patients received conditioning with TBI 14.4 Gy and cyclophosphamide 120 mg/kg (68 vs 74% in Caucasians and non-Caucasians, respectively). As GvHD prophylaxis all patients received cyclosporine-A 5 mg/kg and the majority of patients received 'short course' methotrexate at 15 mg/m 2 on days þ 1, þ 3, þ 6 and þ 7. All patients received prophylaxis with aciclovir, fluconazole, ciprofloxacin and metronidazole.
Demographic data obtained from the British library (www.bl.uk/collection) showed that the proportion of nonCaucasian patients in our study is well represented in comparison to the normal population in the West Midlands region.
End points and statistical analysis Continuity adjusted w 2 tests, Fishers Exact test and the nonparametric Wilcoxon two-sample test were used to assess differences in patient, disease and transplantation characteristics between ethnic groups. 11 The primary end point for analysis was TRM and incidence of aGvHD grade 2 or greater for patients surviving more than 14 days. Secondary end points were cGvHD for patients surviving greater than 100 days with evidence of engraftment, OS, DFS and time to relapse. TRM was defined as death in CR or death related to transplantation where it was not possible to assess disease-status before death. Patients who died from other causes were censored at the time of death. OS was measured from the time of transplantation until death from any cause; DFS was measured from transplantation until disease-relapse or death. Patients still alive at the time of the analysis were censored at the date of last follow-up. Time to relapse was calculated from date of transplant to date of first relapse; patients who did not relapse were censored at either date of death or date of last follow-up as appropriate. Survival curves were constructed using the method of Kaplan and Meier 12 and the log-rank test was used to assess differences between ethnic groups. Data were analysed using the statistical software SAS (SAS Institute, SAS Circle, North Carolina, USA).
Results
Age and gender did not differ notably between the two ethnic groups. However, Caucasian patients were more likely to present with AML than were non-Caucasian patients (28 and 12% respectively, P ¼ 0.02). A significant increase was observed in the number of CMV-positive patients receiving transplants from donors who were also CMV positive in the non-Caucasian group (63 vs 15%, Po0.001). Non-Caucasian patients were more likely to receive stem cells from peripheral blood, 81% compared to 55% in the Caucasian group (P ¼ 0.02, Table 1 ). This was due to donor choice. Furthermore, a higher proportion of acute GvHD grade X2 was observed in the non-Caucasian group compared to that in the Caucasian group (48 and 26%, respectively, P ¼ 0.02, Figure 1 ). There was no difference in diseases status at the time of transplant, in conditioning regimen and GvHD prophylaxis between the two groups to account for the increased aGvHD in the non-Caucasian group.
At the time of analysis 151/251 patients were alive with a median follow-up of 27 months (range 1 month to 8 years). No significant differences were observed between the two groups in terms of OS (P ¼ 0.43) or DFS (P ¼ 0.53). This was because there was increased rate of deaths due to disease relapse in Caucasians compared to non-Caucasians (64 vs 35%). There was no significant difference in disease status at the time of transplant between the two groups (Table 1 ). This suggests that there might be a greater graftversus-tumour effect in the non-Caucasian patients. This, however, can only be explored in the context of a larger study. However, there was a subtle trend showing nonCaucasian patients to have poorer OS, with 64% alive at 12 months post transplant compared to 69% of Caucasian patients (Figure 2) . No difference was detected in time to relapse between ethnic groups (P ¼ 0.67, Figure 3) .
TRM was defined as death from infection, CMV pneumonitis, GvHD, neurotoxicity, radiation, sepsis or respiratory failure or any other transplant-related toxicity. TRM was shown to be the main cause of death in nonCaucasians, in contrast to Caucasians who died mainly of disease (P ¼ 0.02, Table 2 ). Non-Caucasians died sooner after transplant, 19% having died within 6 months of transplantation compared with 9% in the Caucasian group (P ¼ 0.04, Figure 4 ). Causes of death in both groups are outlined in Table 2 .
Discussion
We have shown that a significantly higher proportion of non-Caucasians developed acute GvHD and had significantly higher TRM as compared to Caucasian patients. Median follow-up on live patients was 27 months at the time of analysis. No difference in survival was observed between the two ethnic groups. To our knowledge there is no evidence to suggest that tumour biology or drug pharmokinetics are different in Asians and African black patients. For this reason and also because further subdivision would have made patient numbers in the ethnic group very small, we analysed both groups together. A higher proportion of patients in the non-Caucasian group received Increased aGvHD and TRM in non-Caucasians following allograft M Karanth et al peripheral blood progenitor cells (PBPC). Although some studies suggest that the incidence of cGvHD rather than aGvHD is increased with PBPC as compared to bone marrow transplants, 13, 14 there was no increase in cGvHD in the non-Caucasian group.
Serna 15 et al. demonstrated inferior survival rates in Hispanics when compared with Whites post-allo-SCT. There was no significant difference between Whites and Asians in this study. They hypothesized that unmeasured factors such as SES, structure of health care system, compliance, psychosocial and cultural elements related to ethnicity explained the disparities in survival outcome post transplant. However, this study failed to demonstrate inferior survival in the other ethnic minority groups such as African blacks and Asians.
We have demonstrated significantly higher TRM in the non-Caucasian patients as compared to Caucasian patients. The explanation for higher TRM and increased aGvHD remains to be determined. Extrinsic and intrinsic factors in isolation or combined may play a role. Intrinsic factors such as tumour biology and pharmacokinetics of chemotherapeutic agents and many extrinsic factors such as low SES, nutritional status, post transplant care, presenting with late disease, and access to health care. In the United Kingdom, access to health care system is fairly uniform and hence this factor is unlikely to have contributed to the poorer outcome seen in non-Caucasian patients.
Pollock et al. 2 demonstrated that AA and SS children with ALL had a significantly higher mortality than did white children after adjusting for variables. Similar observations were made by Pui et al. 16 who showed inferior survival in AA patients. However, in this study major biological risk factors were not considered.
In an abstract by Mielcarek et al., 17 patients undergoing both related and unrelated allogeneic transplantation were compared in terms of TRM and GvHD according to their ethnic groups. In an 8-year study period there were only 55 black patients while in the study period there were 1865 white patients. They report significantly higher mortality in black patients as compared to white patients. Severe and more frequent aGvHD were seen in black patients. This difference, however, was not seen among other ethnic groups. Black patients were noted to have more advanced disease at the time of transplant (54.5%) and a longer median interval from diagnosis to transplantation. They concluded that blacks had a significantly greater risk of mortality following allogeneic SCT and postulated that this was associated with biological factors rather than socioeconomic differences.
A recent multicentre study published by Oh et al.
18
compared transplant outcome and GvHD in various ethnic groups, including Japanese, Caucasian Americans (CA), AA, Scandinavians and Irish. They analysed adult and paediatric patients separately and showed that adult Caucasians, AA and Irish patients had significantly higher TRM as compared to Japanese patients. They found no difference in the risk of cGvHD and OS. In the paediatric cohort CA patients had a significantly higher risk of both acute and chronic GvHD. Sekeres et al. 9 showed the poor outcome in AA males as compared to Caucasian patients when treated with similar induction therapy for AML. In this study, data were collected on 2570 patients with de novo AML enrolled to CALGB studies. AA males had significantly lower CR rates than all other groups when adjusted for age, AML-M3 subtype, and white cell count at presentation. Five-year OS and DFS in AA males were also significantly lower. However, in this study the patients were preselected on the basis of their fitness to receive intensive chemotherapy. Data regarding SES and postremission therapy were also not considered.
In our study group, we had more Asians than African blacks in the non-Caucasian group and we show a higher TRM and significant increase in aGvHD even among the Asian subgroup. To the best of our knowledge this has not been previously reported. Although there was a higher proportion of non-Caucasian patients who were CMV positive, only two patients had CMV reactivation in this group during the study period and there was no TRM due to CMV reactivation in either the Caucasian or nonCaucasian group.
There is a paucity of published data on ethnicity and the outcome following allogeneic SCT. In this retrospective study, we have also demonstrated higher TRM and increased aGvHD in non-Caucasian patients. Although we demonstrate similar results to Oh et al. 18 the ethnic group population in this study is quite different from our study and our study includes mainly Asians and African blacks. Multicenter studies or registry analyses are required to confirm whether ethnic origin does indeed affect outcome. If confirmed, the next step is to understand tumour biology in various ethnic groups. Ultimately, changes in approaches to transplantation may be required to improve transplant outcome in this subset of patients. Increased aGvHD and TRM in non-Caucasians following allograft M Karanth et al
